date,title,source
Oct-31-18,Scholar Rock to Present at the Jefferies 2018 London Healthcare Conference,GlobeNewswire
Nov-09-18,Scholar Rock Demonstrates that Highly Specific TGF1 Inhibition Combined with Anti-PD1 Drives Tumor Regression and Survival Benefit in Preclinical Models of Primary Resistance to Checkpoint Blockade Therapy,GlobeNewswire
